AU2010305825A1 - Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor - Google Patents

Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor Download PDF

Info

Publication number
AU2010305825A1
AU2010305825A1 AU2010305825A AU2010305825A AU2010305825A1 AU 2010305825 A1 AU2010305825 A1 AU 2010305825A1 AU 2010305825 A AU2010305825 A AU 2010305825A AU 2010305825 A AU2010305825 A AU 2010305825A AU 2010305825 A1 AU2010305825 A1 AU 2010305825A1
Authority
AU
Australia
Prior art keywords
esi
methyl
pct
alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010305825A
Other languages
English (en)
Inventor
Thomas Russell Clarkson
Fiona Jeremiah
John Kinnaird Ferguson Maclean
Paul David Ratcliffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme BV filed Critical Merck Sharp and Dohme Ltd
Publication of AU2010305825A1 publication Critical patent/AU2010305825A1/en
Assigned to MERCK SHARP & DOHME B.V. reassignment MERCK SHARP & DOHME B.V. Alteration of Name(s) of Applicant(s) under S113 Assignors: MSD OSS B.V.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2010305825A 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor Abandoned AU2010305825A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
US61/251,101 2009-10-13
EP09172872.5 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Publications (1)

Publication Number Publication Date
AU2010305825A1 true AU2010305825A1 (en) 2012-04-19

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010305825A Abandoned AU2010305825A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Country Status (12)

Country Link
US (1) US8841289B2 (enExample)
EP (1) EP2488520B1 (enExample)
JP (1) JP2013507417A (enExample)
KR (1) KR20120100913A (enExample)
CN (1) CN102666540A (enExample)
AU (1) AU2010305825A1 (enExample)
BR (1) BR112012008518A2 (enExample)
CA (1) CA2776835A1 (enExample)
IN (1) IN2012DN02968A (enExample)
MX (1) MX2012004289A (enExample)
RU (1) RU2012119488A (enExample)
WO (1) WO2011045258A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013018735A1 (ja) 2011-07-29 2013-02-07 大正製薬株式会社 アミジン化合物又はその塩
DK2822656T3 (en) 2012-03-07 2017-01-30 Inst Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AU2013264943B2 (en) * 2012-05-22 2018-02-01 King Abdullah University Of Science And Technology Combination comprising parthenolide for use in the treatment of Alzheimer's Disease and other neurodegenerative disorders
WO2015036759A1 (en) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US10183938B2 (en) 2014-12-16 2019-01-22 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
TWI770525B (zh) 2014-12-30 2022-07-11 美商瓦洛健康公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
HK1248222A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂
HK1248220A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂
JP2018504432A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106279211B (zh) * 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
JP2018516973A (ja) 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
US10500205B2 (en) 2015-12-09 2019-12-10 Cadent Therapeutics, Inc. Thienopyrimidinone NMDA receptor modulators and uses thereof
RS60834B1 (sr) 2015-12-09 2020-10-30 Cadent Therapeutics Inc Modulatori heteroaromatskog nmda receptora i njihove upotrebe
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
WO2020004594A1 (ja) * 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
HU231414B1 (hu) * 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
JP7633676B2 (ja) 2018-07-26 2025-02-20 ドメイン・セラピューティクス 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
EP4223760B1 (en) 2018-08-03 2025-06-04 Novartis AG Heteroaromatic nmda receptor modulator and uses thereof
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2021198188A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
JP2023539663A (ja) 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
CN112898290B (zh) * 2021-01-29 2022-08-05 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2025176185A1 (zh) * 2024-02-23 2025-08-28 海思科医药集团股份有限公司 一种braf抑制剂的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
CA2444598A1 (en) * 2001-04-20 2003-10-31 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of gsk-3
WO2003062235A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
NI200800025A (es) * 2005-07-26 2009-03-03 Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
KR20090107994A (ko) 2006-09-11 2009-10-14 엔.브이.오가논 퀴나졸리논 및 이소퀴놀리논 아세트아미드 유도체
CN101573354B (zh) * 2006-12-27 2014-02-12 塞诺菲-安万特股份有限公司 取代的异喹啉类及其作为Rho-激酶抑制剂的用途
JP2010229035A (ja) 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
WO2009062988A1 (en) * 2007-11-14 2009-05-22 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
US20100327809A1 (en) 2008-02-29 2010-12-30 Techno Core International Co., Ltd. Charging apparatus and quality judging apparatus for packed battery

Also Published As

Publication number Publication date
CA2776835A1 (en) 2011-04-21
MX2012004289A (es) 2012-06-12
US20120208796A1 (en) 2012-08-16
BR112012008518A2 (pt) 2016-04-05
WO2011045258A1 (en) 2011-04-21
US8841289B2 (en) 2014-09-23
IN2012DN02968A (enExample) 2015-07-31
RU2012119488A (ru) 2013-11-20
KR20120100913A (ko) 2012-09-12
JP2013507417A (ja) 2013-03-04
EP2488520B1 (en) 2015-09-02
EP2488520A1 (en) 2012-08-22
CN102666540A (zh) 2012-09-12

Similar Documents

Publication Publication Date Title
AU2010305825A1 (en) Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor
CN116194456B (zh) 作为kras抑制剂的杂环化合物的制备及其应用方法
AU2019309987B2 (en) Heterobicyclic compounds for inhibiting the activity of shp2
AU2009302360B2 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
JP6128133B2 (ja) Ｉｇｆ−１ｒ／ｉｒ阻害剤としての５，８−ジヒドロ−６ｈ−ピラゾロ［３，４−ｈ］キナゾリン
CN113061132B (zh) 一类稠环内酰胺类化合物、制备方法和用途
JP2022510980A (ja) ヘテロ芳香族誘導体調節因子、その製造方法及び使用
JP2021518395A (ja) Ｓｈｐ２阻害剤およびその使用
CA2825279A1 (en) New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN112778311B (zh) 含氮并环类衍生物抑制剂、其制备方法和应用
JP2019537610A (ja) Ｆｇｆｒ４阻害剤、その製造方法と薬学的な応用
WO2014060112A1 (en) Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
UA101676C2 (uk) Піримідинові сполуки, композиції і способи застосування
CA2767648A1 (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
KR20090038895A (ko) 융합된 피리미도 화합물
CA2803467A1 (en) New aminopyrazoloquinazolines
AU2021373162B2 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
EP4008719A2 (en) Pyrazolone and pyrimidine compound, and preparation method and use therefor
AU2021348463A9 (en) Indoline compounds and derivatives as egfr inhibitors
AU2022371404A1 (en) Covalent egfr inhibitors and methods of use thereof
WO2009043884A1 (en) Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors
AU2022378269A1 (en) Quinazoline derivative compound and use thereof
CA2716202A1 (en) Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as pkc-theta inhibitors
CA3255932A1 (en) ACTIVE COMPOUNDS AGAINST BROMODOMAINS
TW202246261A (zh) 作為抗癌劑的化合物

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application